Skip to content

The immunological aspects of conventional therapies for the treatment of cervical cancer. An exploratory study to monitor the immunological effects of radiotherapies in cervical cancer patients

The immunological aspects of conventional therapies for the treatment of cervical cancer. An exploratory study to monitor the immunological effects of radiotherapies in cervical cancer patients - The immunological effects of radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35864
Enrollment
30
Registered
2011-10-07
Start date
2011-10-31
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the cervix cervical cancer

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients should be at least 18 years of age; - Patients should be able and willing to provide informed consent; - Patients should have the clinical diagnosis of cervical cancer; - Patients are scheduled for: 1. Primary external beam radiotherapy (EBRT) with intra-uterine brachytherapy (BT); 2. Primary EBRT with intra-uterine brachytherapy (BT) and concurrent chemotherapy (Cisplatin); 3. Primary EBRT with intra-uterine brachytherapy (BT) and combined with hyperthermia; 4. Adjuvant, post-operative external beam radiotherapy (EBRT); 5. Adjuvant, post-operative EBRT with concurrent chemotherapy (Cisplatin).

Exclusion criteria

Exclusion criteria: - Any medical condition that may interfere with the study objectives; - Positive test result for HIV or Hepatitis B; - Any other active malignancy than cervical cancer.

Design outcomes

Primary

MeasureTime frame
The time-related immuneresponse during and after treatment with radiotherapy in cervical cancer patients. T cell phenotypic changes and T cell-related immune cell functional changes will be investigated.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)